Methodological standard · §7
CEI-MS-01 — references
Normative and informative references, and related standards in the same category.
§7References
§7.1Normative references
The following are normative for this standard: compliance with the standard requires compliance with them[1,2,3].
- General Chapter ⟨1225⟩ Validation of Compendial Procedures — United States Pharmacopeia — National Formulary (USP–NF), 2024
- ICH Q2(R2) Validation of Analytical Procedures — ICH Harmonised Guideline, 2023
- General Chapter 2.2.29 Liquid Chromatography — European Pharmacopoeia, 2023
§7.2Informative references
The following are informative: they support the reasoning of the standard without being conditions of compliance[4,5].
- HPLC analysis and purification of peptides — Methods in Molecular Biology, 2007
- Related impurities in peptide medicines — Journal of Pharmaceutical and Biomedical Analysis, 2014
§7.3Related standards
- CEI-MS-08 — Related-substances profiling and the detection of isobaric impurities
- CEI-MS-19 — Purity determination for peptides not retained by conventional reverse-phase chromatography
Numbered reference list
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- United States Pharmacopeial Convention. General Chapter ⟨1225⟩ Validation of Compendial Procedures. United States Pharmacopeia — National Formulary (USP–NF) 2024;USP 2024 Issue 1. identifier not held by the Institute
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q2(R2) Validation of Analytical Procedures. ICH Harmonised Guideline 2023;Step 4 version, 1 November 2023. identifier not held by the Institute
- European Directorate for the Quality of Medicines & HealthCare. General Chapter 2.2.29 Liquid Chromatography. European Pharmacopoeia 2023;11th edition. identifier not held by the Institute
- Mant CT, Chen Y, Yan Z, Popa TV, Kovacs JM, Mills JB, Tripet BP, Hodges RS. HPLC analysis and purification of peptides. Methods in Molecular Biology 2007;386:3–55. doi:10.1007/978-1-59745-430-8_1 · PMID 18604941
- D’Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, De Spiegeleer B. Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis 2014;101:2–30. doi:10.1016/j.jpba.2014.06.012 · PMID 25044089
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.
Compound Evidence Institute · CEI-MS-01/7 · https://compoundevidence.com/methods/rp-hplc-purity/references/ · retrieved 30 July 2026